Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The patient registry dataset (PRiDe)

Seminars in Oncology

Volumn 41, Issue S6, 2014, Pages S4-S13

  Mrugala, Maciej M ^a   Engelhard, Herbert H ^b   Dinh Tran, David ^c   Kew, Yvonne ^d   Cavaliere, Robert ^e   Villano, John L ^f   Annenelie Bota, Daniela ^g   Rudnick, Jeremy ^h   Love Sumrall, Ashley ⁱ   Zhu, Jay Jiguang ^j   Butowski, Nicholas ^k  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ LEVINE CANCER INSTITUTE   (United States)

^j UNIVERSITY OF TEXAS   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG DELIVERY DEVICE; EYE DISEASE; FALLING; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; HEADACHE; HEAT SENSATION; HUMAN; INFECTION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; MONOTHERAPY; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PAIN; PATIENT COMPLIANCE; SEIZURE; SKIN IRRITATION; SKIN MANIFESTATION; SURVIVAL RATE; TREATMENT DURATION; VASCULAR DISEASE; VERY ELDERLY; WEAKNESS; ADOLESCENT; BRAIN NEOPLASMS; CANCER GRADING; ELECTROSTIMULATION THERAPY; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; REGISTER; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; ELECTRIC STIMULATION THERAPY; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; REGISTRIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84908347132     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.09.010     Document Type: Article

References (36)

1. R. Ahmed, M.J. Oborski, M. Hwang, F.S. Lieberman, and J.M. Mountz Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods Cancer Manag Res 6 2014 149 170
2. Q.T. Ostrom, L. Bauchet, F.G. Davis, I. Deltour, J.L. Fisher, and C.E. Langer The epidemiology of glioma in adults: a "state of the science" review Neurooncology 16 7 2014 896 913
3. K. Anton, J.M. Baehring, and T. Mayer Glioblastoma multiforme: overview of current treatment and future perspectives Hematol Oncol Clin North Am 26 2012 825 853
4. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, and R.C. Janzer Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
5. E.T. Wong, K.R. Hess, M.J. Gleason, K.A. Jaeckle, A.P. Kyritsis, and M.D. Prados Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 1999 2572 2578
6. H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, and L.E. Abrey Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
7. J.J. Vredenburgh, A. Desjardins, J.E. Herndon 2nd, J. Marcello, D.A. Reardon, and J.A. Quinn Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 2007 4722 4729
8. A.D. Norden, J. Drappatz, A. Muzikansky, K. David, M. Gerard, and M.B. McNamara An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma J Neurooncol 92 2009 149 155
9. Y.P. Ramirez, J.L. Weatherbee, R.T. Wheelhouse, and A.H. Ross Glioblastoma multiforme therapy and mechanisms of resistance Pharmaceuticals (Basel) 6 2013 1475 1506
10. Y. Soda, C. Myskiw, A. Rommel, and I.M. Verma Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme J Mol Med (Berl) 91 2013 439 448
11. M. Khasraw, and A.B. Lassman Advances in the treatment of malignant gliomas Curr Oncol Rep 12 2010 26 33
12. T.N. Kreisl, L. Kim, K. Moore, P. Duic, C. Royce, and I. Stroud Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 2009 740 745
13. Food & Drug Administration (FDA) approval: NovoTTF-100A System-P100034. Available at http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm254480.htm.
14. E. Fonkem, and E.T. Wong NovoTTF-100A: a new treatment modality for recurrent glioblastoma Exp Rev Neurotherapeut 12 2012 895 899
15. R. Stupp, E.T. Wong, A.A. Kanner, D. Steinberg, H. Engelhard, and V. Heidecke NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality Eur J Cancer 48 2012 2192 2202
16. A.M. Davies, U. Weinberg, and Y. Palti Tumor treating fields: a new frontier in cancer therapy Ann N Y Acad Sci 1291 2013 86 95
17. P.H. Gutin, and E.T. Wong Noninvasive Application of Alternating Electric Fields in Glioblastoma: A Fourth Cancer Treatment Modality Am Soc Clin Oncol Educ Book 32 2012 126 131
18. E.D. Kirson, V. Dbaly, F. Tovarys, J. Vymazal, J.F. Soustiel, and A. Itzhaki Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors Proc Natl Acad Sci U S A 104 2007 10152 10157
19. E.D. Kirson, Z. Gurvich, R. Schneiderman, E. Dekel, A. Itzhaki, and Y. Wasserman Disruption of cancer cell replication by alternating electric fields Cancer Res 64 2004 3288 3295
20. M. Pless, and U. Weinberg Tumor treating fields: concept, evidence and future Exp Opin Invest Drugs 20 2011 1099 1106
21. Instructions for Use. NovoTTF-100A system. March 3, 2012.
22. E.D. Kirson, Y. Wasserman, A. Izhaki, D. Mordechovich, Z. Gurvich, and V. Dbaly Modeling tumor growth kinetics and its implications for TTFields treatment planning. [abstract] Neurooncology (Meeting Abstracts) 12 suppl 4 2010 (NO-54)
23. E.T. Wong, E. Lok, K.D. Swanson, S. Gautam, H.H. Engelhard, and F. Lieberman Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma Cancer Med 3 2014 592 602
24. D.R. Macdonald, T.L. Cascino, S.C. Schold Jr, and J.G. Cairncross Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1990 1277 1280
25. E.T. Wong, Z. Ram, P.H. Gutin, and R. Stupp Updated survival data of the phase III clinical trial of NovoTFF-100A versus best standard chemotherapy for recurrent glioblastoma. [abstract] Neurooncology. (Meeting Abstracts) 13 2011 iii85 iii91 (OT-09)
26. A. Desjardins, D.A. Reardon, A. Coan, J. Marcello, J.E. Herndon 2nd, and L. Bailey Bevacizumab and daily temozolomide for recurrent glioblastoma Cancer 118 2012 1302 1312
27. J.J. Raizer, S. Grimm, M.C. Chamberlain, M.K. Nicholas, J.P. Chandler, and K. Muro A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas Cancer 116 2010 5297 5305
28. R. Soffietti, E. Trevisan, L. Bertero, P. Cassoni, I. Morra, and M.G. Fabrini Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology) J Neurooncol 116 2014 533 541
29. M. Weller, T. Cloughesy, J.R. Perry, and W. Wick Standards of care for treatment of recurrent glioblastoma - are we there yet? Neuro Oncol 15 2013 4 27
30. M. Nagane, R. Nishikawa, Y. Narita, H. Kobayashi, S. Takano, and N. Shinoura Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma Jpn J Clin Oncol 42 2012 887 895
31. E. Archavlis, N. Tselis, G. Birn, P. Ulrich, D. Baltas, and N. Zamboglou Survival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: a retrospective cohort analysis of recurrent glioblastoma multiforme BMJ Open 3 2013 e002262
32. J.N. Greenspoon, W. Sharieff, H. Hirte, A. Overholt, R. Devillers, and T. Gunnarsson Fractionated stereotactic radiosurgery with concurrent temozolomide chemotherapy for locally recurrent glioblastoma multiforme: a prospective cohort study Onco Targets Ther 7 2014 485 490
33. A. Omuro, T.A. Chan, L.E. Abrey, M. Khasraw, A.S. Reiner, and T.J. Kaley Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma Neurooncology 15 2013 242 250
34. M. Giladi, R.S. Schneiderman, Y. Porat, M. Munster, A. Itzhaki, and D. Mordechovich Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields Pancreatology 14 2014 54 63
35. E.D. Kirson, R.S. Schneiderman, V. Dbaly, F. Tovarys, J. Vymazal, and A. Itzhaki Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys 9 2009 1
36. R.S. Schneiderman, E. Shmueli, E.D. Kirson, and Y. Palti TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters BMC Cancer 10 2010 229